GLG Partners Boosts Stake in NPS Pharmaceuticals (NPSP) To 5.74%
More News related to NPSP
- NPS Pharmaceuticals President and CEO Dr. Francois Nader Recognized By Ernst & Young as 2009 Entrepreneur of the Year Finalist in New Jersey
- NPS Pharmaceuticals to Present at Jefferies Healthcare Conference
- Notable Analyst Rating Changes 6/11: RF, FITB, BBT, HBAN, STI, BAC, GSK Upgraded; UNH, TIN, ALV, VPRT Downgraded
- Morning Movers 6/11: STAA, CPST, HGSI, CHDX, MBRX, OBCI Higher; LULU, UNH, LUB, LTON, PNFP Lower
- STAA, MBRX, NPSP, HGSI, CPST, JAZZ, ESLR See Volume and Upside Price Action
In a 13G filing on NPS Pharmaceuticals, Inc. (Nasdaq: NPSP), GLG Partners disclosed a 5.74% stake (2,708,801 Shares) in the company. The firm held 1,925,000 shares at the quater ended 3/31/08. A 13G indicates a 'passive investment.'
GLG Partners is one of the largest alternative asset mangers in the world. The firm’s approach is a multi-strategy approach, offering 40 funds across equity, macro, emerging markets, and credit convertible bond investment products. The firm was founded in 1995 and currently manages $24 billion for high net worth individuals and institutions.
NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of specialty therapeutics for gastrointestinal and endocrine disorders.
Related Categories
13GsStocks Mentioned
-0.15Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
